肝苏胶囊联合阿德福韦酯治疗活动性肝硬化临床观察

目的观察肝苏胶囊联合阿德福韦酯治疗活动性肝硬化的疗效和安全性。方法将87例活动性乙型肝炎肝硬化患者随机分为治疗组（49例）和对照组（38例）,对照组在保肝、对症等常规治疗基础上给予阿德福韦酯胶囊10mg/d治疗,治疗组在对照组基础上给予肝苏胶囊每次3粒,每天3次,疗程24周。结果2组治疗前后比较Child-Pugh评分、肝功能、肝纤维化指标、PLT水平、HBV-DNA载量、脾厚度比较,差异有统计学意义（P〈0.01或P〈0.05）;2组治疗后比较差异有统计学意义（P〈0.01或P〈0.05）。结论肝苏胶囊联合阿德福韦酯治疗活动性乙型肝炎肝硬化能协同改善肝功能,具有明显的抗肝纤维化作用,临床应用安全。

Clinical observation on adefovir dipivoxil combined with Gansu capsule for active liver cirrhosis

Objective To investigate the efficacy and safety on Adefovir Dipivoxil combined with Gansu capsule in treatment of active liver cirrhosis. Methods 87 patients with active hepatitis B together with liver cirrhosis were randomly divided into 49 cases of the treatment group and the control group of 38 cases. The two groups were given Adefovir Dipivoxil 10mg/d treatment on the basis of the conventional therapy such as the liver protection, and expectant treatment. The treatment group was treated with Gansu capsule three times daily on the basis of control group, three pieces once,24-week-course of treatment. Results Child-Pugh score of the two groups decreased,liver function and liver fibrosis index was improved, HBV-DNA load declined,the value of spleen thickness decreased, and the difference of comparison was significant（ P 〈 0.01 or P 〈 0. 05 ） ; the treatment group was superior to the control group （ P 〈 0.01 or P 〈 0.05 ） after the treatment. Conclusion Adefovir Dipivoxil combined with Gansu capsule in treatment of active liver cirrhosis of hepatitis B can make a significant therapeutic effect on active liver fibrosis and can coordinatlv improve liver function.and can supply securitv in clinical annlication.